IGMPI Approvals & Accreditation : Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India, Approved Training Institute of Food Safety and Standards Authority of India (FSSAI), Recognized by Department of Industrial Policy & Promotion, Ministry of Commerce & Industry, Government of India, An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India Empanelled under Ministry of Horticulture and Food Processing, Government of Uttar Pradesh, Affiliated with Life Sciences and Food Industry Sector Skills Council (SSC)
Trusted by organizations & training participants in over 30 countries. Training | Certification | Education | Research

Positive results reported from Udenafil Phase III FUEL Trial by Mezzion Pharma to treat adolescents with SVHD who have undergone Fontan procedure

01st August 2019

Mezzion Pharma Co, a well-known biotech company announced the positive results from phase 3 FUEL trial. It was designed to access the safety and efficacy of udenafil for treating certain adolescents with congenital single ventricle heart disease (SVHD).

Although, Mezzion is prohibited in sharing specific data results at current time due to legal obligation, the company is looking well-ahead to publication of the full results in a peer reviewed journal and the presenting clinical trial data at a major scientific meeting later this year.

The FUEL Trial study included 400 male and female adolescents with a single functional ventricle who had earlier undergone Fontan surgical palliation. Participants were assembled from a total of 30 Pediatric Heart Network (PHN) and auxiliary sites throughout the US, Canada, and Korea. The PHN is sponsored by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health.

As per the reports received, results from FUEL trial and the safety data collected about the drug candidate over other clinical studies, Mezzion Pharma look forward to submit a New Drug Application to the US Food and Drug Administration for seeking approval for the usage of udenafil for treating adolescents with SVHD who have undergone Fontan palliation.

For further enquiries, write to or call us on:
info@igmpiindia.org/ +91 8587838177, +91 8130924488, 0120-2427175, 0120-4375280

Pharmaceuticals | Food | Clinical Research | Healthcare | Medical Coding | Medical Device | Nanotechnology | IPR

Clinical Research Newsletter

Featured Article

GMP: A continous process

Mr Vinod Arora, Principal Advisor, IGMPI

IGMPI Placement Blog

Placement Testimonials

Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like